These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 31544234)

  • 41. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.
    Wilson J; Yao GL; Raftery J; Bohlius J; Brunskill S; Sandercock J; Bayliss S; Moss P; Stanworth S; Hyde C
    Health Technol Assess; 2007 Apr; 11(13):1-202, iii-iv. PubMed ID: 17408534
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Are cancer drugs less likely to be recommended for listing by the Pharmaceutical Benefits Advisory Committee in Australia?
    Chim L; Kelly PJ; Salkeld G; Stockler MR
    Pharmacoeconomics; 2010; 28(6):463-75. PubMed ID: 20465315
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The extent and quality of qualitative evidence included in health technology assessments: a review of submissions to NICE and CADTH.
    Szabo SM; Hawkins NS; Germeni E
    Int J Technol Assess Health Care; 2023 Dec; 40(1):e6. PubMed ID: 38126273
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of the ASCO Value Framework for Anticancer Drugs at an Academic Medical Center.
    Wilson L; Lin T; Wang L; Patel T; Tran D; Kim S; Dacey K; Yuen C; Kroon L; Brodowy B; Rodondi K
    J Manag Care Spec Pharm; 2017 Feb; 23(2):163-169. PubMed ID: 28125363
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?
    Cheng S; McDonald EJ; Cheung MC; Arciero VS; Qureshi M; Jiang D; Ezeife D; Sabharwal M; Chambers A; Han D; Leighl N; Sabarre KA; Chan KKW
    J Clin Oncol; 2017 Aug; 35(24):2764-2771. PubMed ID: 28574778
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
    Low E;
    J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
    [No Abstract]   [Full Text] [Related]  

  • 47. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
    Kim ES; Kim JA; Lee EK
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Can Standard Health Technology Assessment Approaches Help Guide the Price of Orphan Drugs in Canada? A Review of Submissions to the Canadian Agency for Drugs and Technologies in Health Common Drug Review.
    Balijepalli C; Gullapalli L; Druyts E; Yan K; Desai K; Barakat S; Locklin J
    Clinicoecon Outcomes Res; 2020; 12():445-457. PubMed ID: 32922050
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR).
    Masucci L; Beca J; Sabharwal M; Hoch JS
    Pharmacoecon Open; 2017 Dec; 1(4):255-263. PubMed ID: 29441502
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Using pharmacoeconomic analysis to make drug insurance coverage decisions.
    Anis AH; Rahman T; Schechter MT
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 2):119-26. PubMed ID: 10176146
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of Oncology Drug Review Times on Public Funding Recommendations.
    Hussain M; Wong C; Taguedong E; Verma S; Mahsin M; Karim S; Lee-Ying R; Ezeife DA
    Curr Oncol; 2023 Aug; 30(8):7706-7712. PubMed ID: 37623039
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Challenges in striving to simultaneously achieve multiple resource allocation goals: the pan-Canadian Oncology Drug Review (pCODR) example.
    McDonald H; Charles C; Elit L; Gafni A
    J Mark Access Health Policy; 2016; 4():. PubMed ID: 27489586
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Health technology assessment of new drugs for rare disorders in Canada: impact of disease prevalence and cost.
    Rawson NS
    Orphanet J Rare Dis; 2017 Mar; 12(1):59. PubMed ID: 28330479
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Attitude of Iranian Medical Oncologists Toward Economic Aspects, and Policy-making in Relation to New Cancer Drugs.
    Daroudi R; Mirzania M; Zendehdel K
    Int J Health Policy Manag; 2015 Oct; 5(2):99-105. PubMed ID: 26927395
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Evaluation of Anti-cancer Therapies with Reimbursement Limited to Comprehensive Cancer Centres Using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale].
    Büchler T; Melichar B; Vrána D; Lemstrová R; Fínek J; Dušek L; Petráková K; Prausová J
    Klin Onkol; 2017; 30(5):349-360. PubMed ID: 29031037
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Perspectives on Cost and Value in Cancer Care.
    Saltz LB
    JAMA Oncol; 2016 Jan; 2(1):19-21. PubMed ID: 26501848
    [No Abstract]   [Full Text] [Related]  

  • 57. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
    Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
    J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Guidelines for health technologies: specific guidance for oncology products in Canada.
    Mittmann N; Evans WK; Rocchi A; Longo CJ; Au HJ; Husereau D; Leighl NB; Isogai PK; Krahn MD; Peacock S; Marshall D; Coyle D; Taylor SC; Jacobs P; Oh PI
    Value Health; 2012 May; 15(3):580-5. PubMed ID: 22583470
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Examining the Feasibility and Utility of Estimating Partial Expected Value of Perfect Information (via a Nonparametric Approach) as Part of the Reimbursement Decision-Making Process in Ireland: Application to Drugs for Cancer.
    McCullagh L; Schmitz S; Barry M; Walsh C
    Pharmacoeconomics; 2017 Nov; 35(11):1177-1185. PubMed ID: 28770453
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.